This website is intended for UK healthcare professionals only. Not a UK healthcare professional? Click here.

Prescribing Information and Adverse Event Reporting (links to external website):

Managing CVD risk in patients with diabetes and elevated LDL-C

Adult patients with diabetes are 2–3 times more likely to develop CVD and approximately twice as likely to die from heart disease or stroke compared to those without diabetes.1

Cholesterol management is one vital component of a holistic approach to CV risk reduction in diabetes care. When treating patients with diabetes, the greatest reductions in CV risk and mortality are seen with combined long-term risk factor management of blood pressure, HbA1c and lipids2,3

Even after LLT, ≥60% of patients with diabetes do not reach guideline-recommended ESC/EAS 2019 LDL-C goals, therefore remaining at increased risk of CVD.4,*

Join leading experts, Dr. Patrick Holmes and Beverley Bostock, as they delve into key considerations for managing hypercholesterolaemia and mixed dyslipidaemia in patients with diabetes, with a focus on reducing their heightened CV risk through effective lipid-lowering therapies.

In this video, they review current practices for managing patients with diabetes, address common patient concerns and barriers to initiating LLT, and discuss the available treatment options, highlighting the importance of selecting the right therapy for each patient.

Explore the efficacy data for NUSTENDI® and NILEMDO®

*Patients receiving combination therapy of statin + ezetimibe (N=4,516).4

Speaker bios

Dr. Patrick Holmes
Dr. Patrick Holmes

Partner Middleton & Dinsdale Medical Practice, Darlington, Director Goggledocs Education Ltd and Darlington PCN diabetes lead

Dr. Holmes has been a GP Partner at St. George’s Medical Practice, Darlington for 22 years. He is a local clinical commissioner for diabetes. Trustee & committee member for the Primary Care Diabetes Society. Primary Care Diabetes NIHR Research lead for the North East. Associate Editor for Diabetic Medicine. He has also worked as a GPwSI in Diabetes for County Durham and Darlington Foundation Trust. Clinical interests – adult type 2 diabetes, cardiovascular disease prevention & chronic kidney disease.

Read More

Beverley Bostock
Beverley Bostock

Advanced Nurse Practitioner in general practice in Gloucestershire and an Editor in Chief of Practice Nurse journal

She qualified as an RGN at St George’s Hospital London and gained a BSc in Professional Nursing Studies after completing 2 years of an advanced clinical practice MSc at Wolverhampton University. She is an Independent Nurse Prescriber and holds a PGDip in Diabetes, an MSc in Respiratory Care and an MA in Medical Ethics and Law. Beverley’s other qualifications include a Post Graduate Award in Diabetes Therapeutics from Warwick University. Beverley has extensive educational experience developing modules in diabetes and CVD for an Open University-affiliated organisation and is an Expert Witness for a clinical negligence company. She has been a Queen’s Nurse since 2015, a title which is given to nurses who have demonstrated a high level of commitment to patient care and nursing practice. Beverley is a President-Elect of the Primary Care Cardiovascular Society and has worked on the Implementation Steering Group of Public Health England’s CVDPREVENT project and Oxford AHSN’s ‘Prevention of CVD during the pandemic’ guidance. She has also been a Visiting Lecturer in behaviour change at Imperial College London for the MSc in Preventive Cardiology.

Read More

References

  1. British Heart Foundation. UK Factsheet. January 2025. Available at: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf Accessed: September 2025.
  2. NHS. NHS RightCare Pathway: Diabetes. Available at https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2018/07/nhs-rightcare-pathway-diabetes.pdf Access: September 2025.
  3. Yudkin JS, et al. Diabetologia. 2010;53:2079–2085.
  4. Morieri ML, et al. Cardiovasc Diabetol. 2020;19:190.

Abbreviations

ASCVD, atherosclerotic cardiovascular disease; BSc, Bachelor of Science; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; GP, General Practitioner; GPwSI, General Practitioner with a Special Interest; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; MA, Master of Arts; MSc, Master of Sciences; NIHR, National Institue for Health and Care Research; PCI, percutaneous coronary intervention; PCN, Primary Care Network; PGDip, Postgraduate Diploma; RGN, Registered General Nurse.

Job code: UK/BIL/08/25/0004|Date of preparation: September 2025

This is a Daiichi Sankyo site intended for UK healthcare professionals (HCPs) and other relevant decision makers,* where you can find promotional information about Daiichi Sankyo products and professional resources.

So that we can provide you with the most appropriate information, please choose one of the following options:

I am a UK healthcare professional

This website contains promotional information intended for UK healthcare professionals and other relevant decision makers only.

Confirm
I am a member of the public

This website provides members of the UK public with details about Daiichi Sankyo and its medicines. For further information about your health or medicines please consult your doctor, nurse or pharmacist.

Confirm

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who are not healthcare professionals.